Physician profile
Susan A Kessler
NPI 1538105358
$7,635.85
in general payments reported to CMS, 2019-2025
28 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $644 · 2021: $800 · 2022: $1,130 · 2023: $962 · 2024: $1,542 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Gift: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.84 |
| Gift | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,218.12 | 2019-2025 | Rocklatan, Eysuvis, Argos |
| Tarsus Pharmaceuticals, INC. | $1,014.36 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $768.18 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $587.05 | 2020-2024 | Siliq |
| Oyster Point Pharma, INC. | $452.07 | 2022-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $406.96 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $401.27 | 2019-2021 | |
| Horizon Therapeutics Plc | $392.91 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $353.78 | 2019-2025 | Cequa |
| Allergan, INC. | $346.62 | 2019-2022 | |
| Abbvie INC. | $315.97 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $282.76 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $282.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $261.58 | 2019-2023 | |
| Astellas Pharma US INC | $122.88 | 2024 | Izervay |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $106.86 | 2020-2025 | Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $43.05 | 2025 | Syfovre |
| Thea Pharma INC. | $39.34 | 2022-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $36.65 | 2020 | |
| Mallinckrodt Hospital Products INC. | $32.56 | 2025 | Acthar |
| Dompe US, INC. | $25.71 | 2025 | Oxervate |
| Haag-Streit USA, INC. | $25.00 | 2025 | |
| Shire North American Group INC | $24.83 | 2019 | |
| Biotissue Holdings INC. | $23.12 | 2025 | |
| Spark Therapeutics, INC. | $22.14 | 2022 | |
| Merz Pharmaceuticals, LLC | $17.73 | 2025 | Xeomin |
| Lombart Brothers, INC. | $16.75 | 2019 | |
| Eyepoint US, INC. | $15.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.